First-Line Immune Checkpoint Inhibitor-Based Sequential Therapies for Advanced Hepatocellular Carcinoma: Rationale for Future Trials is a research paper published in Liver Cancer (2021). On theSindex it has a DataRank of 0. It has been cited 50 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Worldwide Cancer Research
Grant: 16-0026
National Institutes of Health
Grant: 3R01MD012565-03S1
Multilevel factors for racial/ethnic and socioeconomic disparities in prognosis of hepatocellular carcinoma
FWCI
4.37
Citation Percentile
1.0%
Citation Trend
Fields of Study
Keywords
Sustainable Development Goals